Evogene Ltd. (NASDAQ:EVGN) Short Interest Up 414.3% in August

Evogene Ltd. (NASDAQ:EVGN) was the target of a significant increase in short interest during the month of August. As of August 14th, there was short interest totaling 232,078 shares, an increase of 414.3% from the July 30th total of 45,127 shares. Currently, 2.9% of the company’s shares are sold short. Based on an average trading volume of 994,693 shares, the short-interest ratio is presently 0.2 days.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Evogene in a research report on Wednesday, July 8th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

Evogene Price Performance

EVGN stock traded down $0.01 during mid-day trading on Wednesday, reaching $0.54. The company had a trading volume of 16,020 shares, compared to its average volume of 920,865. The company has a market capitalization of $4.74 million, a price-to-earnings ratio of -0.60 and a beta of 1.40. Evogene has a 52 week low of $0.37 and a 52 week high of $1.50. The stock has a 50 day simple moving average of $0.53 and a two-hundred day simple moving average of $0.70.

Insider Buying and Selling

In other Evogene news, Director Leon Recanati bought 460,000 shares of Evogene stock in a transaction dated Tuesday, August 11th. The shares were bought at an average price of $0.64 per share, with a total value of $294,400.00. Following the purchase, the director owned 1,343,886 shares of the company’s stock, valued at $860,087.04. This trade represents a 52.04% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 7.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of EVGN. XTX Topco Ltd bought a new stake in shares of Evogene in the fourth quarter valued at about $25,000. Jane Street Group LLC increased its position in Evogene by 58.0% during the first quarter. Jane Street Group LLC now owns 33,732 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 12,387 shares during the period. Finally, Citadel Advisors LLC raised its stake in Evogene by 169.4% in the 3rd quarter. Citadel Advisors LLC now owns 57,575 shares of the biotechnology company’s stock worth $66,000 after purchasing an additional 36,206 shares in the last quarter. 10.40% of the stock is owned by institutional investors.

About Evogene

Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.

In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens.